Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. - Wikidata - wikimedia - TriplyDB

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

http://www.wikidata.org/entity/Q33435836

about

Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment Epidemiology and treatment patterns of epithelial ovarian cancer.Implementing Genome-Driven Oncology.A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovaria Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.PARP inhibitors in ovarian cancer: evidence, experience and clinical potential Emerging therapies for breast cancer "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors Drugging the Cancers Addicted to DNA Repair.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer.Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.Pathogenesis and heterogeneity of ovarian cancer.Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.Pathways to Genome-targeted Therapies in Serous Ovarian Cancer.CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.BRCA mutation in ovarian cancer: testing, implications and treatment considerations.Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?Niraparib for the treatment of ovarian cancer.Unravelling the biology of SCLC: implications for therapy.The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.Therapeutic targeting and patient selection for cancers with homologous recombination defects.The role of biomarkers in the management of epithelial ovarian cancer.The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.Niraparib: First Global Approval.Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.Treatment strategies for DNA repair-deficient prostate cancer.Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population.Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts.Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

P2860

Q28066904-073DCF8A-D4D5-4A81-B7C9-35EC3B3CB2FA Q30235358-211439AC-C199-4F4D-8404-9E1A1D91D506 Q30235979-BBAE8768-14D0-4EE3-B63C-6B355734D709 Q33438615-E7C5F9CF-FE14-46E8-B87F-AA3CA808D7A1 Q33563963-C4245E00-4C45-4587-BA13-2376AA8055B1 Q33605912-7ABB49B1-7BDC-47F6-8775-00599604EB32 Q33617949-89B07C26-5F22-4F3C-A3E1-D73169238320 Q33618910-310B4E6B-E286-43F6-8A1E-53E6B66ED5C1 Q33702497-C2E880B8-D71E-490A-816D-ECC11E8B9671 Q33704050-AB7AA269-DF73-45FE-A526-F3D1696ED25B Q33738954-B439A9EF-4741-4834-B3E9-6D56C390C02A Q36320168-57A98A3D-41CD-4FC8-90DE-880BFBE78772 Q36369910-BADB98A7-4972-41E8-9DBD-630C357947CA Q37546692-3F0E7EC7-18EA-43AF-A4C2-69E95E23B278 Q37573430-81871178-43A0-4EBC-A09D-F189A246A736 Q37607283-46D8EAA9-4848-4E60-8F6F-4EFD8FCC9750 Q37620476-CD7F9A94-D532-40FB-BC7E-9B0977C05549 Q37631697-E22C1839-DAE3-45B9-8E70-9A6A291A875A Q37661436-C420538D-B17D-426E-9B63-FAECB0808C20 Q38621094-5C3BCDC4-5CF4-43FE-826B-ACBF9AE8D42F Q38639827-16FF38BA-8523-4836-8F28-DEE2388879FD Q38644661-26E6B5DE-A08C-4DB4-A2D0-C8C5E547BD6A Q38645200-AC130895-A815-4D3A-8CDC-6B9D30F56FC1 Q38653318-25783D00-EEDC-4925-A337-FD89AECC22BD Q38693066-02173C0C-0E83-4CD2-AD60-4420778E9F1F Q38744399-A4262550-5714-4CEE-8383-D66AF0B2432F Q38769421-438329C5-3642-44A7-9C88-E05784BC2DB5 Q39190147-9E009723-49A2-4159-8E7B-9D0FA86F6E90 Q39251572-FA2B55F5-6B4F-43DD-A76A-D029779A9E8B Q39281140-8C2E769C-3034-4884-BDA1-7429B74C7F5F Q39282981-9C522191-CBCB-434B-930F-B6EE0F1E1C9A Q39285185-E5351AD5-0EEE-4A1A-BF68-8CB5A679C15A Q39309080-2BD0BAF7-8410-47D8-915B-7CB68CFDA3A6 Q39345771-4EF28C09-DF27-4989-A858-B34026A26758 Q39391417-9AE29822-DB6A-4FA5-AA8E-3737A0772224 Q40120413-33434EE2-ADB9-4038-A66F-5A1BE6FCB6CA Q40230451-519DCB91-D1D0-493C-9201-0FE0A7173228 Q41155792-42788086-E221-43C1-8D14-D083835C3890 Q41279420-E7DC3089-18FF-4409-83F0-94C794EED5A9 Q41279772-23E28D1E-6413-4D3C-9120-64FDDBF3DAA3

P2860

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

http://www.wikidata.org/entity/Q33435836

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

@ast

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

@en

type

label

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

@ast

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

@en

prefLabel

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

@ast

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

@en

P1433

Q33435836-CB8D9DAF-479E-4307-B198-393EE9CC4653

P1476

Q33435836-2AACC634-2E1E-4449-BBB7-84717C8B9B59

P2093

Q33435836-060417F3-44A1-4B7B-93E8-E75AD6D622CF

Q33435836-1CF76AAD-CC63-4FB5-9330-37472E4BF030

Q33435836-21410246-BFC2-4613-B4CC-0F2813D2929C

Q33435836-2BC7CE74-AA8B-4AF8-B535-0E5188D32D26

Q33435836-2C6CEB65-62A5-4FC5-B266-04953C95E949

Q33435836-3258118D-9665-427D-ABFF-EB36A5A40647

Q33435836-3D63F6DD-CF1F-4913-A61A-2EF2206015BA

Q33435836-42CAEAAF-AC1C-4BBF-A908-65AF52F9F310

Q33435836-469501C2-BBB5-4C2E-BA49-98B9B4BC8778

Q33435836-5E414DBB-D1BD-4114-9DCB-19B9CCFCF12A

P304

Q33435836-95B49DC9-516E-4475-8243-A7178F909609

P31

Q33435836-C324B776-E2AD-42D4-86D3-17E097DC9C5E

P356

Q33435836-A068C2A1-6BFC-4448-AF8D-81BBB845639C

P407

Q33435836-8E24ADDE-53ED-4F42-B5E8-1CDED8172999

P433

Q33435836-FB04C10C-4D93-4142-8952-4E7D6D279B9C

P478

Q33435836-BB9E47F7-C8B7-4DBF-8195-D67D7502CA41

P50

Q33435836-77A366D9-DCDD-4872-8C3D-77394C4D7C8D

Q33435836-83CE0AC7-F4F8-47D6-8E66-C9B6FBFA83B0

Q33435836-8A15BB80-0ADC-4C92-B48A-6ACE0350322A

Q33435836-C0385E68-3D2F-4035-81DB-F4A988761168

P577

Q33435836-39A8DEFC-CD60-4953-8123-A9DC3096BAFE

P698

Q33435836-F4B36379-35F1-49F2-B4E7-B12C6C19B55D

P921

Q33435836-97EE39EF-5AEE-4CA4-A4CB-4D27854F897B

P356

P1433

The New England Journal of Medicine

P1476

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

@en

P2093

Amit M Oza

http://www.w3.org/2001/XMLSchema#string

Andreas du Bois

http://www.w3.org/2001/XMLSchema#string

Andrés Redondo

http://www.w3.org/2001/XMLSchema#string

Anna V Tinker

http://www.w3.org/2001/XMLSchema#string

Antonio González-Martín

http://www.w3.org/2001/XMLSchema#string

Benedict Benigno

http://www.w3.org/2001/XMLSchema#string

Bobbie J Rimel

http://www.w3.org/2001/XMLSchema#string

Bradley J Monk

http://www.w3.org/2001/XMLSchema#string

Christian Marth

http://www.w3.org/2001/XMLSchema#string

ENGOT-OV16/NOVA Investigators

http://www.w3.org/2001/XMLSchema#string

P304

2154-2164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1611310

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Domenica Lorusso

Radosław Mądry

P577

2016-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27717299

http://www.w3.org/2001/XMLSchema#string

P921